Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NPY1R | P25929 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116380 | 0.91 | NPC1 (0.53) | MEN1KMT2ANPY1RALDH1A1NPY2R | |
| SCHEMBL21116592 | 0.91 | KMT2A (0.47) | MEN1KMT2AALDH1A1MAPTHTT | |
| SCHEMBL21116381 | 0.90 | TP53 (0.45) | PPARDMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL24116652 | 0.88 | ALDH1A1 (0.50) | POLBNPY1RALDH1A1NPY2RMAPK1 | |
| SCHEMBL21116984 | 0.86 | DRD2 (0.44) | MEN1KMT2AALDH1A1GAAHTT | |
| SCHEMBL19577396 | 0.80 | PPARD (0.56) | PPARDMEN1KMT2APOLBNPY1R | |
| SCHEMBL24322995 | 0.76 | PPARD (0.58) | PPARDMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL20999620 | 0.75 | ATF4 (0.50) | MEN1KMT2APOLBALDH1A1GAA | |
| SCHEMBL23263844 | 0.74 | KMT2A (0.46) | MEN1KMT2APOLBALDH1A1MAPK1 | |
| SCHEMBL19569418 | 0.73 | ATF4 (0.74) | MEN1KMT2APOLBNPY1RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | PPARD 1954/4885MEN1 4714/4885KMT2A 4320/4885 |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | PPARD 1954/4885MEN1 4714/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.